Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012;2:3–44
   PubMed Web of Science ®Google Scholar
• Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 2011;14:67–77
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487–97
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33–56
   PubMed Web of Science ®Google Scholar
• Hegyi G, Szigeti GP, Szasz A. Hyperthermia versus oncothermia: Cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med 2013;2013:672873–84
   PubMed Web of Science ®Google Scholar
• Bleehen NM. Hyperthermia in the treatment of cancer. Br J Cancer Suppl 1982;5:96–100
   PubMedGoogle Scholar
• Cheung AY, Neyzari A. Deep local hyperthermia for cancer therapy: External electromagnetic and ultrasound techniques. Cancer Res 1984;44:S4736–44
   PubMed Web of Science ®Google Scholar
• Habash RW, Bansal R, Krewski D, Alhafid HT. Thermal therapy, part 2: Hyperthermia techniques. Crit Rev Biomed Eng 2006;34:491–542
   PubMedGoogle Scholar
• Huang HS, Hainfeld JF. Intravenous magnetic nanoparticle cancer hyperthermia. Int J Nanomedicine 2013;8:2521–32
   PubMed Web of Science ®Google Scholar
• Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol J 2011;6:1342–7
   PubMed Web of Science ®Google Scholar
• Kozissnik B, Bohorquez AC, Dobson J, Rinaldi C. Magnetic fluid hyperthermia: Advances, challenges, and opportunity. Int J Hyperthermia 2013;29:706–14
   PubMed Web of Science ®Google Scholar
• Sadhukha T, Wiedmann, TS, Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 2013;34:5163–71
   PubMed Web of Science ®Google Scholar
• Laurent S, Bridot JL, Elst LV, Muller RN. Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem 2010;2:427–49
   PubMed Web of Science ®Google Scholar
• Liu G, Gao J, Ai H, Chen X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small 2013;9:1533–45
   PubMed Web of Science ®Google Scholar
• Amstad E, Textor M, Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale 2011;3:2819–43
   PubMed Web of Science ®Google Scholar
• Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010;70:6303–12
   PubMed Web of Science ®Google Scholar
• Hansen L, Larsen EK, Nielsen EH, Iversen F, Liu Z, Thomsen K, et al. Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. Nanoscale 2013;5:8192–201
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: Preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett 2012;7:144–56
   PubMed Web of Science ®Google Scholar
• Jadhav NV, Prasad AI, Kumar A, Mishra R, Dhara S, Babu KR, et al. Synthesis of oleic acid functionalized Fe3O4 magnetic nanoparticles and studying their interaction with tumor cells for potential hyperthermia applications. Colloids Surf B Biointerfaces 2013;108:158–68
   PubMed Web of Science ®Google Scholar
• Balivada S, Rachakatla RS, Wang H, Samarakoon TN, Dani RK, Pyle M, et al. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: A mouse study. BMC Cancer 2010;10:119–27
   PubMed Web of Science ®Google Scholar
• Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomedicine 2011;6:591–603
   PubMed Web of Science ®Google Scholar
• Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim H, et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 2006;89:338–47
   PubMed Web of Science ®Google Scholar
• Gaikwad SM, Gunjal L, Junutula AR, Astanehe A, Gambhir SS, Ray P. Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models. PLoS One 2013;8:e55971
   PubMed Web of Science ®Google Scholar
• Desai S, Laskar S, Pandey BN. Autocrine IL-8 and VEGF mediate epithelial-mesenchymal transition and invasiveness via p38/JNK-ATF-2 signalling in A549 lung cancer cells. Cell Signal 2013;25:1780–91
   PubMed Web of Science ®Google Scholar
• Rana S, Jadhav NV, Barick KC, Pandey BN, Hassan PA. Polyaniline shell cross-linked Fe3O4 magnetic nanoparticles for heat activated killing of cancer cells. Dalton Trans 2014;43:12263–71
   PubMed Web of Science ®Google Scholar
• Jost SC, Collins L, Travers S, Piwnica-Worms D, Garbow JR. Measuring brain tumor growth: A combined BLI/MRI strategy. Mol Imaging 2009;8:245–53
   PubMed Web of Science ®Google Scholar
• Kregel KC. Molecular biology of thermoregulation, invited review: Heat shock proteins: Modifying factors in physiologicalstress responses and acquired thermotolerance. J Appl Physiol 2002;92:2177–86
   PubMed Web of Science ®Google Scholar
• Carper SW, Duffy JJ and Gerner EW. Heat shock proteins in thermotolerance and other cellular processes. Cancer Res 1987;47:5249–55
   PubMed Web of Science ®Google Scholar
• Liu KS, Liu H, Qi JH, Liu QY, Liu Z, Xia M, et al. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett 2012;318:180–8
   PubMed Web of Science ®Google Scholar
• Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008;3:1089–95
   PubMed Web of Science ®Google Scholar
• Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. AKT forms an intracellular complex with heat shock protein 90 (Hsp90) and CDC37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858–66
   PubMed Web of Science ®Google Scholar
• Sato S, Fujita N, Tsuruo T. Modulation of AKT kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000;97:10832–37
   PubMed Web of Science ®Google Scholar